228 related articles for article (PubMed ID: 25480314)
1. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.
Castellano D; Grande E; Valle J; Capdevila J; Reidy-Lagunes D; O'Connor JM; Raymond E
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1099-114. PubMed ID: 25480314
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
3. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
4. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
[TBL] [Abstract][Full Text] [Related]
6. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.
Strosberg JR; Fisher GA; Benson AB; Anthony LB; Arslan B; Gibbs JF; Greeno E; Iyer RV; Kim MK; Maples WJ; Philip PA; Wolin EM; Cherepanov D; Broder MS
World J Gastroenterol; 2015 Feb; 21(8):2450-9. PubMed ID: 25741154
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
8. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
9. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
Bilici A
Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731
[TBL] [Abstract][Full Text] [Related]
10. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
11. Current medical treatment of pancreatic neuroendocrine tumors.
Yalcin S; Oyan B; Bayraktar Y
Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276
[TBL] [Abstract][Full Text] [Related]
12. The molecular pathogenesis and management of bronchial carcinoids.
Cakir M; Grossman A
Expert Opin Ther Targets; 2011 Apr; 15(4):457-91. PubMed ID: 21275849
[TBL] [Abstract][Full Text] [Related]
13. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
Strosberg JR; Chan JA; Ryan DP; Meyerhardt JA; Fuchs CS; Abrams T; Regan E; Brady R; Weber J; Campos T; Kvols LK; Kulke MH
Endocr Relat Cancer; 2013 Jun; 20(3):383-90. PubMed ID: 23572164
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of digestive neuroendocrine tumors].
Rougier P; Toma C; Fabri MC; Ducreux M
Ann Gastroenterol Hepatol (Paris); 1995; 31(2):117-20. PubMed ID: 7618833
[No Abstract] [Full Text] [Related]
15. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.
Hörsch D; Schmid KW; Anlauf M; Darwiche K; Denecke T; Baum RP; Spitzweg C; Grohé C; Presselt N; Stremmel C; Heigener DF; Serke M; Kegel T; Pavel M; Waller CF; Deppermann KM; Arnold R; Huber RM; Weber MM; Hoffmann H
Oncol Res Treat; 2014; 37(5):266-76. PubMed ID: 24853787
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
Pavel ME; Wiedenmann B
Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?
Perysinakis I; Aggeli C; Kaltsas G; Zografos GN
Hormones (Athens); 2016; 15(1):15-22. PubMed ID: 26732156
[TBL] [Abstract][Full Text] [Related]
18. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
Yalcin S
Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397
[TBL] [Abstract][Full Text] [Related]
19. Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.
Singh S; Dey C; Kennecke H; Kocha W; Maroun J; Metrakos P; Mukhtar T; Pasieka J; Rayson D; Rowsell C; Sideris L; Wong R; Law C
Ann Surg Oncol; 2015 Aug; 22(8):2685-99. PubMed ID: 25366583
[TBL] [Abstract][Full Text] [Related]
20. The use of chemotherapy in the management of neuroendocrine tumors.
Oberg K
Endocrinol Metab Clin North Am; 1993 Dec; 22(4):941-52. PubMed ID: 8125079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
